Novel immunotherapies in multiple myeloma

• Verfasst von: Rasche, Leo [VerfasserIn]
• Verfasst von: Wäsch, Ralph [VerfasserIn]
• Verfasst von: Munder, Markus [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Raab, Marc-Steffen [VerfasserIn]
• Titel: Novel immunotherapies in multiple myeloma
• Titelzusatz: chances and challenges
• Verf.angabe: Leo Rasche, Ralph Wäsch, Markus Munder, Hartmut Goldschmidt and Marc S. Raab
• E-Jahr: 2021
• Jahr: July 1, 2021
• Umfang: 11 S.
• Fussnoten: Gesehen am 04.02.2022
• Titel Quelle: Enthalten in: Haematologica
• Ort Quelle: Pavia : Ferrata Storti Foundation, 2014
• Jahr Quelle: 2021
• Band/Heft Quelle: 106(2021), 10, Seite 2555-2565
• ISSN Quelle: 1592-8721
• DOI: doi:10.3324/haematol.2020.266858
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1788617878

Abstract

In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.